Introduction
Acquired genetic alterations that lead to defects in apoptosis are common in human cancers and are thought to promote tumorigenesis by allowing cells to survive under conditions that would otherwise trigger a cell death response. Unlike normal cells, cancer cells survive despite DNA damage, in the absence of required growth factors and under the hypoxic conditions encountered when a tumor outgrows its blood supply. To metastasize, tumor cells must survive transit through the blood stream and colonize a foreign tissue, although normal epithelial cells die when deprived of substratum interactions. Importantly, the propensity of tumor cells to undergo apoptosis is a critical determinant of their sensitivity to many chemotherapeutic agents. Therefore, defects in apoptotic signaling contribute to tumor initiation and progression, and can lead to drug resistance and treatment failure.
Gene silencing associated with aberrant methylation of CpG island-containing gene promoters serves as an alternative, epigenetic mechanism contributing to loss of gene function in human cancers (reviewed in Jones and Baylin, 2002; Laird, 2005) . CpG islands are CpG dense regions that flank the 5 0 end of more than half the genes in the human genome (Bird, 1986; Lander et al., 2001) . Although normally maintained in an unmethylated state, CpG islands can become aberrantly methylated in cancer. This methylation is accompanied by a shift to a repressed chromatin conformation, which renders the associated gene transcriptionally silent. Once established, this state is mitotically heritable and contributes to the stable silencing of tumor suppressor and other genes. Several proapoptotic genes succumb to epigenetic silencing in human tumors, including CASP8, the TNFrelated apoptosis-inducing ligand (TRAIL) receptors TNFRSF10A and TNFRSF10B, the caspase-9 adaptor APAF1 and the death-associated protein kinase, DAPK (Kissel et al., 1997; Teitz et al., 2000; Soengas et al., 2001; van Noesel et al., 2002; Furukawa et al., 2005; Horak et al., 2005) , suggesting that acquired epigenetic alterations also contribute to apoptotic resistance during tumor progression.
In a screen for targets of methylation-mediated silencing, we identified a gene TMS1 (for Target of Methylation-mediated Silencing), that is methylated and silenced in a significant proportion of human breast cancers (Conway et al., 2000) . TMS1 was also independently identified by Masumoto et al. (1999) as a protein that forms cytoplasmic 'specks' during retinoic acid induced differentiation or drug-induced apoptosis in HL60 cells, and called ASC. Subsequent studies by our lab and others have implicated the epigenetic silencing of TMS1 in a number of other tumor types, including melanomas, glioblastomas, non-small cell lung cancers, gastric and colorectal cancers (Moriai et al., 2002; Guan et al., 2003; Virmani et al., 2003; Yokoyama et al., 2003; Stone et al., 2004) . Ectopic expression of TMS1 suppresses the growth of breast cancer cells, consistent with a role in tumor suppression (Conway et al., 2000) .
At present, the precise function of TMS1 and the consequences of its silencing during carcinogenesis are not known. TMS1 encodes a bipartite adaptor protein containing an N-terminal pyrin domain (PYD) and a C-terminal caspase recruitment domain (CARD), two members of the death domain fold superfamily of protein-protein interaction domains that are found in proteins that mediate apoptosis and inflammation. There is evidence supporting a role for TMS1 in both of these processes. Evidence from overexpression studies indicates that TMS1 can drive apoptosis in a Bax and caspase-9-dependent manner Ohtsuka et al., 2004) , and antisense-mediated knockdown of TMS1 protects cells from apoptosis induced by cytotoxic agents (Masumoto et al., 1999) . TMS1 has also been implicated in the extrinsic apoptotic pathway, as forced oligomerization or co-expression with CARD12/Ipaf stimulates caspase-8-dependent apoptosis . TMS1 is also reported to be an integral component of the 'inflammasome,' a multiprotein complex that regulates the maturation of proinflammatory cytokines in cells of myeloid lineage (Martinon et al., 2002) . Indeed, recent evidence from knockout mice indicates that TMS1 is required for the secretion of interleukin-1b (IL-1b) in response to bacterial pathogens in macrophages (Mariathasan et al., 2004; Yamamoto et al., 2004) . Whether it plays a similar, or perhaps additional, role in epithelial cells is not known.
Currently, the natural upstream stimulus for TMS1-dependent apoptosis is not well defined, and its regulation and function in epithelial cells has not been extensively studied. In this study, we examined the role of TMS1 in the cellular response to initiators of the extrinsic (death receptor) and intrinsic (mitochondrial) cell death pathways in breast epithelial cell lines and normal diploid fibroblasts. We find that TMS1 expression is induced in breast epithelial cells in response to the death receptor ligands TRAIL and tumor necrosis factor-a (TNFa). The induction by TNFa was specific to epithelial cells and required both the nuclear factorkB (NF-kB) and jun kinase (JNK) signaling pathways. In contrast, we found little impact of DNA damaging agents on TMS1 expression in this study. Furthermore, we show that TMS1 is not required for NF-kB or caspase-8 activation induced by death receptor ligands in MCF7 cells, but promotes cleavage and activation of caspase-8 independently of death receptor-ligand interactions. These data indicate that TMS1 is both regulated by and promotes death receptor signaling in breast epithelial cells. Epigenetic silencing of TMS1 may therefore contribute to carcinogenesis by dampening the cellular response to death receptor ligands.
Results
TMS1 is normally highly expressed in immune cells, particularly in neutrophils and cells of the macrophage/ monocyte lineage. Previous studies have shown that TMS1 is induced in these cell types in response to proinflammatory stimuli including IL-1b, LPS and TNFa (Shiohara et al., 2002; Stehlik et al., 2003) , although the exact mechanism of this upregulation has not been addressed. TMS1 is also expressed in many epithelial cell types (Masumoto et al., 2001) . We have previously shown that in normal breast tissue, TMS1 is selectively expressed in the ductal and lobular epithelium, but is absent from the underlying myoepithelium and stromal cells (McConnell and Vertino, 2004) . At present little is known about the factors that normally regulate TMS1 expression, and the function of the protein in cells of non-immune origin has not been extensively studied.
To gain insight into the regulation and function of TMS1, we characterized the response of TMS1 to death receptor ligands and genotoxic agents in normal and neoplastic breast epithelial cells. TMS1 protein levels were determined by Western blot analysis ( Figure 1 ) and mRNA levels were determined by quantitative real-time reverse transcriptase PCR (RT-PCR) (Figure 2 ). Treatment of the breast cancer cell line MCF7 with TNFa resulted in a time-dependent increase in TMS1 protein levels ( Figure 1a ) and a 5-fold induction in TMS1 mRNA after 24 h (Figure 2a ). TRAIL treatment also resulted in an upregulation of TMS1 protein and message, although to a lesser extent (2-fold) and with delayed kinetics relative to TNFa (Figures 1a and 2a) . In contrast, treatment with mitomycin C resulted in a modest upregulation of TMS1 at later timepoints (Figures 1a and 2a ), while etoposide treatment had no effect on TMS1 expression in MCF7 cells at either the protein or mRNA level (Figures 1a and 2a ). That treatment with etoposide and mitomycin C elicited a normal p53-dependent DNA damage response in this cell line was confirmed by an observed stabilization of endogenous p53 and a concomitant upregulation of the p53 target gene p21 (Figure 1a) .
A second TMS1 positive breast cancer cell line, MDA MB468, was also tested with similar results (Figures 1b  and 2b ). Treatment with TNFa induced a robust upregulation of TMS1 protein and message, whereas the effects of TRAIL were more modest (Figures 1b and  2b) . MDA MB468 cells are p53 compromised and thus would not be expected to undergo p53-dependent transcriptional response to DNA damage. Accordingly, the DNA damaging agents etoposide and mitomycin C had no effect on the expression of TMS1 in this cell line (data not shown).
To determine if the effects of these agents on TMS1 expression were particular to epithelial cells, we also examined the impact of death receptors and DNA damaging agents on TMS1 expression in IMR90 normal human diploid fibroblasts. Unlike breast epithelial cells, TRAIL and TNFa had little effect on the expression of TMS1 protein (Figure 1c ) or mRNA ( Figure 2d ) in IMR90 fibroblasts. That TNFa failed to affect TMS1 levels could be due to the absence of TNF receptors or other cell type-dependent differences in components of the TNFa signaling pathway (see below). To test this, we also examined the expression of IL-1b, a well-documented target of TNFa stimulation, in these cells. Treatment of IMR90 cells with TNFa induced an approximately 4-fold increase in the levels of IL-1b mRNA, as measured by conventional RT-PCR (data not shown), confirming that the TNFa response is intact in IMR90 fibroblasts.
These data indicate that the upregulation of TMS1 by TNFa is cell type-dependent. Although etoposide treatment induced the stabilization of endogenous p53 and upregulation of p21 as expected for these p53 wild-type cells, it had a relatively minor effect on TMS1 protein levels (1.5-to 1.8-fold increase, Figure 1c ) and no effect on TMS1 mRNA levels ( Figure 2d ).
We also examined the effect of TNFa treatment on TMS1 expression in the immortalized, non-transformed breast epithelial cell line MCF10A. TNFa treatment resulted in a ninefold upregulation of TMS1 message in this cell line (Figure 2c ), thus the upregulation of TMS1 by TNFa in the breast cancer cell lines does not appear to be a consequence of transformation. Consistent with the findings in MCF7 cells and IMR90 cells, etoposide treatment had no effect on TMS1 mRNA expression in MCF10A cells (Figure 2c ). Taken together, these data indicate that TMS1 is upregulated by TNFa in breast epithelial cells, but not human fibroblasts, whereas agents that induce DNA damage and elicit an endogenous p53 response have little effect on TMS1 expression in either cell type. is upregulated in response to TNFa and TRAIL, but not DNA damaging agents. (a) MCF7 cells were treated with 30 ng/ml TNFa, 100 ng/ml TRAIL plus 1 mg/ml 6 Â polyhistidine crosslinking antibody, 50 mM etoposide, or 0.25 mg/ml mitomycin C and cell lysates were collected at the indicated time points. Total cellular proteins were subjected to Western blot analysis using antibodies to TMS1, p53 and p21 as indicated. b-tubulin served as a loading control. (b) MDA MB468 cells were treated over 48 h with 30 ng/ml TNFa or 100 ng/ml TRAIL plus 1 mg/ml 6 Â polyhistidine crosslinking antibody and analysed for TMS1 and b-tubulin protein levels by Western blot analysis. (c) IMR90 cells were treated over 48 h with 30 ng/ml TNFa, 100 ng/ml TRAIL plus 1 mg/ml 6 Â polyhistidine crosslinking antibody or 50 mM etoposide and analysed for TMS1, p53, p21 and b-tubulin protein levels by Western blot analysis. Figure 2 Effect of death receptor ligands and DNA damaging agents on the expression of TMS1 mRNA. (a) MCF7 cells were treated with 30 ng/ml TNFa, 100 ng/ml TRAIL plus 1 mg/ml 6 Â polyhistidine crosslinking antibody, 50 mM etoposide or 0.25 mg/ml mitomycin C, and total cellular RNA was isolated at the indicated timepoints. TMS1 expression levels were quantified by reverse transcription and real-time PCR analysis. We next investigated the mechanism of TNFainduced upregulation of TMS1. The interaction of TNFa with its membrane receptors TNFRI and II initiates downstream signaling through the jun kinase (JNK) pathway and the IkB kinase (IKK) pathway, culminating in activation of the transcription factors activator protein 1 (AP-1) and NF-kB, respectively (Natoli et al., 1997; Devin et al., 2000; Wajant et al., 2003) . To determine whether activation of JNK plays a role in TNFa-induced upregulation of TMS1, MCF7 cells were treated with TNFa in the presence of the JNK inhibitor SP600125 (Bennett et al., 2001) . Inhibition of JNK signaling blocked the TNFa-induced upregulation of TMS1 mRNA and protein in a dose-dependent manner (Figure 3a and b). To control for the efficiency of JNK inhibition by SP600125, parallel samples were also analysed for phosphorylated c-jun (Ser 63) protein levels ( Figure 3b ). At concentrations of SP600125 that were sufficient to block TNFa-induced phosphorylation of c-jun, upregulation of TMS1 was also blocked ( Figure 3b ).
To further investigate the role of the JNK pathway, we also examined the response of TMS1 to TNFa treatment in the presence of small interfering RNA (siRNA) directed against JNK1 and 2 ( Li et al., 2004) . We found that knockdown of JNK1/2 resulted in a slight upregulation (1.5-fold) in the basal levels of TMS1 mRNA and protein. However, TNFa-induced upregulation of TMS1 was blocked in the presence of JNK1/2 siRNA, as was the phosphorylation of c-jun, similar to the results observed with the chemical inhibitor (Supplementary Figure 1 ). Taken together, these results indicate that TNFa-induced TMS1 upregulation is mediated at least in part by JNK signaling.
To determine if TNFa-induced activation of NF-kB contributes to TMS1 upregulation, MCF7 cells were treated with TNFa in the absence or presence of an adenoviral vector expressing a dominant-negative form of inhibitor of kB (IkBa) (Ad-mIkBa, S32A, S36A) (Mayo et al., 2003) . The IkBa super-repressor contains alanines instead of serines at positions 32 and 36, and as a consequence cannot be phosphorylated by the IKK complex or degraded by the 26S proteasome (Brockman et al., 1995; Mayo et al., 2003) . Expression of the dominant-negative IkBa thus sequesters NF-kB in the cytoplasm, thereby preventing NF-kB dependent transcription (Brockman et al., 1995; Mayo et al., 2003) . The expression of IkBa super-repressor blocked TNFainduced upregulation of TMS1 mRNA and protein in a dose-dependent manner (Figure 3c and d). As shown in Figure 3d , TNFa induced the phosphorylation and subsequent degradation of endogenous IkBa, confirming that the NF-kB pathway was activated. As expected, the stabilized dominant-negative IkBa mutant was unaffected by TNFa-induced activation of the NF-kB pathway ( Figure 3d ).
Canonical NF-kB acts as a heterodimer comprised of the p65/RelA and p50 subunits (Baeuerle and Data represent the mean of duplicate PCR determinations, which in general varied by less than 10%. Shown is a representative of three independent experiments. (f) Protein lysates from parallel cultures were fractionated by SDS-PAGE and subjected to western blot analysis using antibodies to TMS1, p65/RelA and GAPDH. (g and h) MCF7 cells were left untreated or were pretreated with 0.5, 1, 2 or 4 mg/ml cycloheximide for 1 h, followed by treatment with 30 ng/ml TNFa for 24 h. TMS1 mRNA and protein expression were analysed by real-time RT-PCR (g) and Western blot analysis (h). Shown is a representative of three independent experiments.
Role of TMS1/ASC in death receptor signaling MJ Parsons and PM Vertino Baltimore, 1996; Baldwin, 1996) . As a further test for the requirement of NF-kB, we examined the impact of siRNA-mediated knockdown of p65/RelA on TNFainduced upregulation of TMS1. Knockdown of p65/ RelA also blocked TNFa-induced upregulation of TMS1 mRNA and protein (Figure 3e and f), suggesting that NF-kB containing the p65/RelA subunit mediates TNFa-induced upregulation of TMS1. Together with the above results, these data indicate that both JNK and NF-kB signaling contribute to the TNFa-induced upregulation of TMS1. NK-kB and JNK activity are known to stimulate the rapid expression of a number of proinflammatory and antiapoptotic genes, some of which could themselves be contributing to the TNFa-induced upregulation of TMS1. The time-frame of TMS1 induction following TNFa stimulation, which was not observed until 24 h after treatment (Figures 1 and 2) , is also suggestive of the involvement of a TNFa-regulated intermediate. To address this possibility, MCF7 cells were treated with TNFa in the presence of cycloheximide to block new protein synthesis. At concentrations sufficient to block new protein synthesis (as indicated by a block in TMS1 protein induction by TNFa), cycloheximide had no effect on TNFa-induced upregulation of TMS1 mRNA (Figure 3g and 3h) . We also examined the effects of TNFa on the stability of the TMS1 message. MCF7 cells were pretreated with 1 mg/ml Actinomycin D for 1 h followed by the addition of 30 ng/ml TNFa and TMS1 message levels were determined by real time RT-PCR. The half-life of the TMS1 message was approximately 24 h in control cells and was not significantly altered by treatment with TNFa (data not shown). These data indicate that neither the synthesis of a TNFa-regulated intermediate nor alterations in message stability contribute to the TNFa-induced upregulation of TMS1 message.
The above data are most consistent with a direct affect of TNFa on TMS1 transcription. To address this possibility, reporter studies were performed. A luciferase reporter construct containing 1254 bp upstream of the TMS1 translation start site (Levine et al., 2003) was transfected into MCF7 cells, and the response to TNFa treatment or co-expression of p65/RelA was determined. A reporter construct containing five copies of a consensus NF-kB response element driving luciferase was used as a positive control. Although TNFa induced a 3-fold increase in luciferase expression from the consensus NF-kB reporter, it had no effect on TMS1 promoter-driven reporter activity ( Supplementary Figure 2) . Similarly, although co-expression of p65/RelA induced a 12-fold increase in luciferase activity from the NF-kB reporter, there was no effect on the TMS1 promoter construct (Supplementary Figure 2) . To rule out the possibility that a cis-acting sequence contained within the TMS1 promoter was masking the effect of TNFa on TMS1 transcription, we also examined the response of a series of TMS1 promoter deletion constructs to TNFa. Again, TNFa had little impact on the activity of the TMS1 promoter (data not shown). Taken together, these data indicate that the effect of TNFa on TMS1 expression may require sequences distal to the promoter.
We next sought to test whether the upregulation of TMS1 might play a role in the downstream cellular events induced by TNFa. In macrophages, TMS1 is an integral part of the inflammasome, a multimeric complex responsible for the activation of proinflammatory caspases (i.e. caspases-1 and -5) and subsequent processing and secretion of cytokines (Mariathasan et al., 2004) . Whether or not this complex forms in response to physiologic stimuli in epithelial cells, or if it forms in response to TNFa, has not been addressed. We therefore examined the impact of TNFa-induced upregulation of TMS1 on caspase-1 activation. MCF7, MDA MB468 and MCF10A cells were treated with TNFa over the course of 48 h as described in Figure 1 , followed by Western blot analysis using an antibody recognizing procaspase-1 and its cleavage products. We found that despite upregulation of TMS1, TNFa treatment had no impact on the basal levels of procaspase-1 and did not induce significant cleavage of caspase-1 in MCF10A or MDA MB468 cells (data not shown). Interestingly, procaspase-1 was undetectable in MCF7 cells. Thus, the TNFa-induced upregulation of TMS1 does not appear to drive caspase-1 activation in breast epithelial cells.
As discussed above, TNFa signaling stimulates the activities of the NF-kB and JNK signaling pathways. This is achieved through binding of TNFa to the TNFa receptor (TNFR), which in turn recruits TRADD and RIP or TRAF2 to induce activation of the IKK complex (Natoli et al., 1997; Kelliher et al., 1998) and JNK (Yeh et al., 1997) respectively. Previous reports have suggested that TMS1 can either promote or inhibit NF-kB signaling depending on cell type, the coexpression of specific adaptor proteins and/or TMS1 expression levels Manji et al., 2002; Stehlik et al., 2002; Wang et al., 2002) . The vast majority of these studies have utilized ectopic expression of TMS1. To examine the involvement of endogenous TMS1 in NF-kB signaling, we determined the impact of TMS1 knockdown on TNFa or TRAIL-induced activation of NF-kB in MCF7 cells. Knockdown of TMS1 with siRNA had no effect on activation of NF-kB in response to TRAIL or TNFa (Figure 4a ). These data indicate that TMS1 is not required for TNFa-or TRAILinduced activation of NF-kB in breast epithelial cells.
To further test the involvement of TMS1 in NF-kB signaling, we utilized HEK 293 cells (which lack endogenous TMS1 expression) that have been engineered to express TMS1 from an ecdysone-inducible promoter (referred to as MTMS22) . Cellular levels of TMS1 can be titrated in this system by varying the concentration of the inducing agent, ponasterone A (ponA). In pilot experiments, we determined conditions that induce nearphysiologic levels (0.3 mM ponA) or supraphysiologic levels (5 mM ponA) of TMS1 by comparison to the endogenous protein levels in MCF7 cells (data not shown). At supraphysiologic levels, TMS1 alone induced a modest (5-fold) increase in NF-kB activity, which was significantly less (approximately 30-to 40-fold) than that induced by physiologic stimuli (see below). Using this system, we examined the impact of TMS1 expression on NF-kB activity induced by Fas, TNFa or TRAIL. Treatment of MTMS22 cells with Fas, TNFa or TRAIL alone resulted in a robust (150-to 200-fold) induction of NF-kB activity (Figure 4b ). However, even at supraphysiologic levels, TMS1 expression had no effect on TNFa-or Fas-induced NF-kB reporter activity (Figure 4b) . Similarly, neither the degree nor the kinetics of IkBa degradation were altered by TMS1 expression in MTMS22 cells (Figure 4c ). At high TMS1 expression levels, there was an approximate 25% inhibition of TRAIL-induced NF-kB activity (Figure 4b ). Taken together these data indicate that TMS1 does not significantly induce NF-kB activity on its own, nor does it influence NF-kB signaling induced by TNFa or Fas.
In addition to stimulating NF-kB and JNK signaling, TNFa and TRAIL can induce apoptosis. In this scenario, TNF-bound TNFRI (or TRAIL to the TRAIL receptors DR4 or DR5) recruits the adaptor protein FADD via homophilic death domain interactions to form the death-inducing signaling complex (DISC) (Chinnaiyan et al., 1996; Hsu et al., 1996; Ashkenazi and Dixit, 1998) . The subsequent recruitment of procaspase-8 to the DISC allows for its cleavage and activation resulting in the activation of downstream effector caspases (i.e. caspase-3 and -7) and ultimately apoptosis. To test the involvement of TMS1 in death receptor-induced apoptosis, MCF7 cells were treated with TRAIL or TNFa in the presence of siRNA against TMS1. In the presence of cycloheximide, TNFa and TRAIL induced cleavage of caspase-8 (Figure 5a and b) , which was not impacted by siRNA-mediated knock- (c) MTMS22 cells were left untreated or treated with 0.3 mM ponA. The following day, cells were treated with 20 ng/ml TNFa, and total cellular protein was isolated at the indicated timepoints. Protein lysates were fractionated by SDS-PAGE and subjected to Western blot analysis using antibodies to IkBa, TMS1, and b-tubulin.
Role of TMS1/ASC in death receptor signalingdown of TMS1. These data indicate that TMS1 is dispensable for caspase-8 activation induced by death receptor ligands in breast epithelial cells. To further examine the impact of TMS1 on caspase-8-dependent apoptosis, we determined the effect of TMS1 overexpression in MCF7 cells. Western analysis illustrated that TMS1 overexpression induced cleavage of caspase-8, and the caspase-8 target c-FLIP (Figure 5c ). We also examined the role of TMS1 in caspase-8-dependent apoptosis in MTMS22 cells. Treatment of MTMS22 cells with 5 mM ponA to induce TMS1 expression resulted in the cleavage of caspase-8 and subsequent cleavage of the death substrate PARP, an indication of the downstream activation of effector caspases (e.g. caspase-3) and apoptosis. TMS1-induced cleavage of caspase-8 and PARP was blocked by coexpression of CrmA, a viral protein that specifically inhibits caspase-8 (Tewari and Dixit, 1995; Srinivasula et al., 1996) , illustrating that TMS1-induced apoptosis is dependent on caspase-8 activity. Taken together, the above data indicate that TMS1 is not required for death receptor-induced activation of caspase-8, but is sufficient to induce cleavage of caspase-8 and subsequent apoptosis, independent of a death receptor stimulus. Thus, the upregulation of TMS1 following death receptor signaling may function as a feed-forward loop that amplifies the apoptotic stimulus induced by TNFa or TRAIL.
Discussion
TMS1 is a novel tumor suppressor gene that is subject to frequent epigenetic silencing in several different tumor types, including breast, gliomas, melanomas and nonsmall cell lung cancers, however the mechanism by which TMS1 silencing promotes carcinogenesis is not well understood (Conway et al., 2000; Moriai et al., 2002; Guan et al., 2003; Virmani et al., 2003; Yokoyama et al., 2003; Stone et al., 2004) . Here, we examined the role of TMS1 in the cellular response of breast epithelial cells and human fibroblasts to death receptor activation and DNA damaging agents. We find that, in both transformed and non-transformed breast epithelial cells, TMS1 is upregulated in response to TNFa. This response was cell type-dependent and did not occur in normal fibroblasts. In contrast, DNA damaging agents that elicit a p53-dependent apoptotic response have a relatively minor impact on TMS1 expression in either cell type. In testing whether the upregulation of TMS1 might play a role in the downstream events induced by TNFa, we found that TMS1 was not necessary for TNFa-induced activation of caspase-8 or NF-kB activation, but could drive caspase-8 cleavage and subsequent apoptosis independently of a death receptor stimulus. These data suggest that TMS1 is both regulated by, and is an effector of, TNFa-induced apoptosis.
Previous studies indicate that TMS1 is upregulated in response to cytokines such as IL-1b, IFN-g, TNFa and LPS in immune cells (Shiohara et al., 2002; Stehlik et al., 2003) , however, the mechanism of this regulation was not determined. We found here that TMS1 is also regulated by TNFa in breast epithelial cells. Upon binding to its surface receptors TNFRI or TNFRII, TNFa induces receptor trimerization and recruitment of death domain-containing adaptor protein TRADD to the receptor's cytoplasmic death domains. The subsequent recruitment of RIP and TRAF2 leads to activation of downstream kinases and signaling through the IKK/NF-kB and JNK/AP-1 pathways (Yeh et al., 1997; Kelliher et al., 1998; Lin et al., 2000) . We found that the upregulation of TMS1 by TNFa was dependent upon the activities of both the NF-kB and JNK signaling pathways, and in particular required the p65/RelA subunit of NF-kB. The finding that TNFa-induced upregulation of TMS1 message and protein did not involve the synthesis of an intermediate or alterations in the stability of the TMS1 message suggests that there is a direct effect of TNFa on TMS1 transcription. Indeed, there are several putative AP-1 and NF-kB sites both upstream and downstream of the TMS1 transcription start site that could contribute to TNFa-induced upregulation of TMS1. In subsequent studies aimed at were pretreated with 2 mg/ml cycloheximide for 30 min, followed by treatment with 30 ng/ml TNFa (a) or 100 ng/ml TRAIL plus 1 mg/ ml 6 Â polyhistidine crosslinking antibody (b) for 4 h. Protein lysates were subjected to Western blot analysis for caspase-8, TMS1 and either GAPDH or b-tubulin as indicated. (c) Overexpression of TMS1 induces caspase-8 cleavage in MCF7 cells. MCF7 cells were transfected with 1 mg empty vector (pcDNA3.1), or 1-2 mg TMS1 expression construct (pcDNA-TMS1). Cell lysates were collected after 24 h and subjected to Western blot analysis using antibodies to TMS1, capsase-8, and b-tubulin. (d) TMS1-induced capsase-8 activation and PARP cleavage is blocked by CrmA. MTMS22 cells were transfected with 6 mg empty vector (pcDNA3.1) or 6 mg of a CrmA expression construct (pcDNACrmA). After 48 h, cells were left untreated or treated with 5 mM ponA. The following day, total cellular protein was isolated and subjected to Western blot analysis using antibodies to TMS1, caspase-8, PARP p85, and b-tubulin.
defining the cis elements that mediate transcriptional regulation by TNFa, we found that there is no effect of TNFa treatment or p65 co-expression on transcription from a TMS1 reporter construct containing >1000 bp of upstream promoter sequence in several cell types (Supplementary Figure 2 and data not shown) . One potential explanation for these findings is that TNFainduced upregulation of TMS1 requires cis elements distal to the promoter. Alternatively, the regulation of TMS1 by TNFa may require a specific chromatin environment not represented in the transiently transfected reporter construct. Consistent with this idea, we have observed that TNFa-treatment induces local alterations in chromatin structure at the TMS1 locus by DNaseI hypersensitive site analysis (data not shown). Further studies will be needed to elucidate the exact mechanism by which TNFa influences TMS1 expression in breast epithelial cells.
NF-kB signaling is important for proper immune function and is often dysregulated in cancer. One proposed role for TMS1 is in the regulation of NF-kB. Previous studies addressing the impact of TMS1 on NF-kB activity are largely conflicting and have shown that TMS1 can promote or inhibit NF-kB activity depending on the stimulus and the co-expression of other adaptor proteins such as the PYPAFs or members of the pyrin family. For example, co-expression of TMS1 with the adaptor proteins PYPAF1/cryopyrin, PYPAF5 or PYPAF7 stimulates NF-kB activity Manji et al., 2002; Wang et al., 2002) , whereas other reports indicate that overexpression of either a full-length TMS1 or the pyrin domain of TMS1 inhibits NF-kB activity induced by TNFa, Bcl-10 or Nod-1 (Stehlik et al., 2002) . Most of these studies utilize overexpression of TMS1 or forced interactions between TMS1 and other adaptor proteins, which may not be physiologically relevant. To this end, a recent study by Mariathasan et al. (2004) showed that TMS1 is dispensable for IkBa degradation, ERK1/2 activation and NF-kB activation in response to LPS and TNFa in macrophages from TMS1 À/À mice. In addition, cryopyrin does not induce NF-kB activity alone or in the presence of physiologic levels of TMS1 in HEK 293 cells (Yu et al., 2005) . Similarly, we find here that neither complete knockdown of endogenous TMS1 in breast epithelial cells nor restoration of TMS1 expression in HEK 293 cells has any impact on NF-kB activity or IkBa degradation in response to TNFa, TRAIL or Fas. Thus, it seems that TMS1 is dispensable for NF-kB signaling. Whether it functions in a feedback mechanism to inhibit NF-kB, as suggested by some studies (Stehlik et al., 2002) , remains to be determined. However, in our hands even high-level expression of TMS1 in MTMS22 cells had no effect on TNFa-or Fas-induced activation of NF-kB.
Although TNFa-induced signaling through the NF-kB and JNK pathways is generally thought to promote survival and proliferation through the upregulation of anti-apoptotic and pro-inflammatory target genes, there is also evidence that the NF-kB and JNK pathways promote apoptosis under certain circumstances. For example, JNK knockout mice are resistant to UVinduced apoptosis (Tournier et al., 2000) . Likewise, c-junÀ/À cells are resistant to apoptosis and instead undergo cell cycle arrest in response to UV damage (Shaulian et al., 2000) . Fas ligand is upregulated by NF-kB and AP-1 following T-cell activation, and the subsequent Fas-mediated cell death is dependent upon intact NF-kB signaling (Kasibhatla et al., 1998 (Kasibhatla et al., , 1999 . Indeed, recent profiling studies examining the spectrum of TNFa-induced, NF-kB-regulated genes include several with pro-apoptotic functions (Zhou et al., 2003; Tian et al., 2005) . TMS1 may be another example of an NF-kB/JNK-regulated factor that functions in a proapoptotic capacity. Previous work from our lab and others has shown that TMS1 induces apoptosis when overexpressed (Masumoto et al., 1999; McConnell and Vertino, 2000; Richards et al., 2001; Ohtsuka et al., 2004) . This apoptosis can be blocked by dominant negative mutants of caspase-9 and is dependent on Bax, implicating the mitochondrial pathway Ohtsuka et al., 2004) . In contrast, apoptosis induced by co-expression of TMS1 with the adapter Ipaf/CARD12 or by forced oligomerization of TMS1 was shown to be dependent on caspase-8 . We show here that TMS1 can induce the activation of caspase-8 and apoptosis, both of which are blocked by CrmA. Thus, the mechanism by which TMS1 induces apoptosis may be stimulus and/or context-dependent. Nevertheless, the implications of our studies are that NF-kB-and JNKmediated upregulation of TMS1 serves to promote apoptosis.
The finding that TMS1 is upregulated by TNFa and can induce apoptosis prompted us to examine the role of TMS1 in death receptor-mediated apoptosis. Our siRNA experiments indicate that TMS1 is not required for activation of caspase-8 in response to TNFa or TRAIL, yet TMS1 overexpression promotes caspase-8 cleavage and subsequent apoptosis independent of a death receptor stimulus in both HEK 293 and MCF7 epithelial cells. One possibility is that the upregulation of TMS1 by TNFa, while not required for initial activation of caspase-8, serves to amplify the apoptotic signal induced by death receptor ligation. Current models indicate that death receptors elicit an apoptotic response through ligand-induced recruitment of the adaptor protein FADD and procaspase-8 to the receptors' cytoplasmic surface to form the DISC (Ashkenazi and Dixit, 1998; Sharp et al., 2005) , allowing for activation of the procaspase through induced proximity (Salvesen and Dixit, 1999; Shi, 2004) . However, there is mounting evidence that caspase-8 can also be activated independently of DISC formation. For example, neither FADD nor caspase-8 are recruited to the membrane-associated TNFRI signaling complex in response to TNFa, yet both factors are required for TNFa-induced apoptosis (Harper et al., 2003) . Recent studies suggest that, unlike that of TRAIL and Fas, apoptosis induced by TNFa involves the sequential activation of two independent complexes; one at the cell membrane consisting of the TNFRI, the adaptor TRADD, and the NF-kB signaling adaptors TRAF2 and RIP1, and a second cytoplasmic complex containing FADD and caspase-8 that forms after receptor internalization and/or dissociation of the ligand from the receptor (Harper et al., 2003; Micheau and Tschopp, 2003; Muppidi et al., 2004) . Thus, the possibility exists that TMS1 drives caspase-8 cleavage by engaging a cytoplasmic pool of caspase-8. Indeed, there is evidence that TMS1 interacts directly with caspase-8, and colocalizes with caspase-8 in the cytoplasm in co-transfection experiments Hasegawa et al., 2005) . Consistent with this idea, Masumoto et al. (2003) showed that TMS1-induced apoptosis cannot be blocked by a dominant-negative FADD mutant consisting only of the death domains. Such mutants might be expected to interfere with recruitment of FADD and caspase-8 to the receptor, but perhaps not activities within the cytoplasmic complex.
Recently, it was suggested that TMS1 is a direct downstream target of the p53-mediated response to genotoxic stress in human fibroblasts and breast epithelial cells (Ohtsuka et al., 2004) . These authors showed that TMS1 is strongly induced by adenoviraldriven or inducible overexpression of p53, and to a lesser extent by treatment with mitomycin C or ionizing radiation, the latter of which was dependent on p53. Here we find that relative to cytokines like TNFa, such agents have a relatively minor impact on TMS1 expression. In particular, quantitative real-time RT-PCR showed no more than a 2-fold induction of TMS1 message in response to etoposide or mitomycin C treatment (Figure 2) . Similar results were obtained in all three wild-type p53 cell types tested (MCF7, MCF10A and IMR90) and with agents known to induce different forms of DNA damage, including etoposide, mitomycin C and UV irradiation (data not shown). In contrast, the upregulation of TMS1 by TNFa appeared to be p53-independent and occurred in both p53 wild-type (MCF10A, MCF7) and p53 mutant (MDA MB468) epithelial cells. Moreover, reporter constructs containing an intact TMS1 promoter, including a putative p53-binding site, failed to respond to etoposide when transfected into MCF7 or IMR90 cells (data not shown). Thus, whereas p53 may have some impact on expression of TMS1, it may be indirect. Alternatively, the regulation of TMS1 by genotoxins may involve transcriptional crosstalk between p53 and NF-kB (Webster and Perkins, 1999) as has been described for other pro-apoptotic NF-kB target genes, such as DR5 (Shetty et al., 2005) .
In summary, we have shown here that TMS1 is upregulated by TNFa in breast epithelial cells in an NF-kB and JNK-dependent manner. While TMS1 is not required for the activation of caspase-8 following death receptor stimulation, overexpression of TMS1 can promote caspase-8 activation. Our data are consistent with a model in which the upregulation of TMS1 by death receptor signaling in breast epithelial cells may function to amplify the apoptotic signal induced by TNFa. Therefore, one important consequence of epigenetic silencing of TMS1 in breast and other cancers may be an attenuated response to cytokines such as TNFa and/or resistance to therapeutic regimens that rely on caspase 8-dependent apoptosis, such as TRAILrelated therapies. Indeed, TNFa and TRAIL have no impact on TMS1 expression in breast cancer cell lines where the endogenous gene is methylated, such as MDA MB231 breast cancer cells (Levine et al., 2003, and unpublished observations) . Thus, reactivation of TMS1 through inhibition of DNA methylation may provide an opportunity to restore sensitivity to death receptor and caspase 8-dependent signaling and apoptosis.
Materials and methods
Cell lines, drug treatments and reagents MCF7 and MDA MB468 breast cancer cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in DMEM (4.5 g/l glucose) plus 10% fetal calf serum and 2 mM glutamine. MCF10A cells were obtained from the Karmanos Cancer Institute (Detroit, MI, USA) and maintained in DMEM/F12 plus 5% FCS, 20 ng/ml epidermal growth factor, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 mg/ml insulin, and 2 mM glutamine. IMR90 normal human diploid fibroblasts were obtained from the National Institute on Aging Cell Repository and maintained in EMEM with 10% FCS and 2 mM glutamine. The generation of HEK 293 cells expressing an ecdysone-inducible myc-tagged TMS1 (MTMS22) have been described previously and were maintained in DMEM (4.5 g/l glucose) plus 10% FCS, 2 mM glutamine, 600 mg/ml G418 and 400 mg/ml zeocin (Invitrogen, Carlsbad, CA, USA). Etoposide, mitomycin C and cycloheximide were purchased from Sigma (St Louis, MO, USA). His-tagged recombinant human TRAIL, 6 Â polyhistidine crosslinking antibody and recombinant human TNFa were purchased from R&D Systems (Minneapolis, MN, USA). The JNK inhibitor SP600125 was purchased from Biomol (Plymouth Meeting, PA, USA). The dominant-negative IkBa adenovirus (Ad-mIkBa) was a gift from Dr Leland Chung (Emory University). PonA was purchased from Invitrogen. Activating anti-Fas antibody was purchased from Upstate Biotechnology.
Immunoblotting and antibodies Cells were pelleted, washed three times in 1 Â PBS, and lysed with RIPA buffer containing 1 Â protease inhibitors (Complete Mini Protease Inhibitor Cocktail, Roche, Indianapolis, IN, USA), 1mM sodium orthovanadate, and 10 mM sodium fluoride (Sigma, St Louis, MO, USA). Total protein (100 mg) was separated on a 15% SDS-PAGE gel, transferred to PVDF or nitrocellulose (BioRad, Hercules, CA, USA), and probed with the indicated primary antibody. Immunocomplexes were detected by incubation with horseradish peroxidase-conjugated secondary antibody and chemiluminescence detection (Pierce, Rockford, IL, USA). The antibodies used were: anti-ASC (MBL), b-tubulin (Sigma), p53 (AB-6, Oncogene), p21 Reverse transcription and real-time PCR Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Total RNA was treated with amplification-grade DNase I (Invitrogen) and reverse-transcribed (RT) using random hexamer priming and MMLV-reverse transcriptase (Invitrogen). A 50 Â dilution (1 ml) of the RT reaction was amplified in duplicate using iQ SYBR Green Supermix (BioRad) and the MyIQ real-time detection system. Reaction conditions included a hot start (3 min, 951C), followed by 50 cycles of (951C, 10 s; 551C, 60 s). Melt curve analysis was performed to ensure a single product species. Parallel reactions were performed using primers to 18S rRNA as an internal control. Relative starting quantities were calculated by comparison to a common standard curve generated with a dilution series of MCF10A cell cDNA that was included in each run. Primers for real-time PCR analysis were for TMS1, 5 0 -TCC AGC AGC CAC TCA ACG-3 0 and 5 0 -GCA CTT TAT AGA CCA GCA-3 0 ; and for 18S, 5 0 -GAG GGA GCC TGA GAA ACG G-3 0 and 5 0 -GTC GGG AGT GGG TAA TTT GC-3 0 .
siRNA experiments MCF7 cells (2.0 Â 10 5 ) were seeded in six-well plates and transfected the next day with 200 nM of the indicated siRNA using Oligofectamine (Invitrogen). TMS1 and p65 siRNA duplexes were purchased from Dharmacon (Lafeyette, CO, USA). The sequence of the TMS1 siRNA was: 5 0 -CGA GGG UCA CAA ACG UUG A dTdT-3 0 (sense), and the sequence of the p65 siRNA was: 5 0 -GCC CUA UCC CUU UAC GUC A dTdT-3 0 (sense). The JNK siRNA was purchased from Sigma (St Louis, MO, USA) and targets a common sequence in both Jnk1 and Jnk2 mRNA (Li et al., 2004) . The sequence of the JNK1/2 siRNA was: 5 0 -AAA GAA UGU CCU ACC UUC U dTdT-3 0 (sense). Dharmacon Lamin A/C siControl was used to control for any non-specific off-target effects of siRNA transfection.
NF-kB reporter assays
For MCF7 cells, 2.0 Â 10 5 cells were seeded in six-well plates and transfected the following day with 200 nM siRNA targeting TMS1 or Lamin A/C as described above. After 48 h, cells were transfected with 1 mg of an NF-kB responsive luciferase reporter construct (pNF-kB-Luc, Stratagene) and 50 ng of a renilla luciferase reporter (pRL-TK, Promega) as a control for transfection efficiency using 3 ml FuGene6 (Roche) per well. After 24 h, the transfection medium was replaced with fresh medium or medium containing 30 ng/ml TNFa or 100 ng/ ml 6 Â his-tagged recombinant human TRAIL plus 1 mg/ml 6 Â polyhistidine crosslinking antibody. After an additional 8 h, cells were lysed and firefly luciferase and renilla luciferase activities were determined using the Dual-Luciferase Reporter Assay system (Promega) according to the manufacturer's directions. For MTMS22 cells, 8.0 Â 10 4 cells were seeded in 24-well plates and transfected the next day with 200 ng of the NF-kB luciferase reporter construct and 10 ng of pRL-TK using 0.6 ml of FuGene6 (Roche) per well. The following day, TMS1 expression was induced by the addition of 0.3 or 5 mM ponA to the medium. After 24 h, the transfection medium was replaced with fresh medium or medium containing 1 mg/ml anti-Fas activating antibody, 20 ng/ml TNFa, or 20 ng/ml 6 Â his-tagged recombinant human TRAIL plus 1 mg/ml 6 Â polyhistidine crosslinking antibody. After 8 h, cells were lysed and firefly luciferase and renilla luciferase activities were determined using the Dual-Luciferase Reporter Assay system (Promega).
Plasmid transfections MCF7 cells, (4.0 Â 10 5 ) were seeded in six-well plates and transfected the following day with 1 mg pcDNA3.1 þ or 1-2 mg pcTMS1 (McConnell and Vertino, 2000) using 6 ml Lipofectamine (Invitrogen). Protein lysates were collected 24 h following transfection. For MTMS22 cells, 4.0 Â 10 6 cells were seeded in 10 cm dishes and transfected the following day with 6 mg pcDNA3.1 þ or pcDNA-CrmA (gift from Dr Margaret Offermann, Emory University) using 36 ml Lipofectamine. TMS1 expression was induced the following day by the addition of 5 mM ponA, and protein lysates were collected after 24 h.
TMS1 promoter studies
A genomic HindIII-NcoI fragment containing 1254 bp upstream of the TMS1 translation start codon was cloned into the pGL3 luciferase reporter plasmid (Stratagene) to generate pTMS1-1254-Luc, as previously described (Levine et al., 2003) . MCF7 or MTMS22 cells (8.0 Â 10 4 ) were seeded in 24-well plates and transfected the next day with the indicated plasmids using 0.6 ml of FuGene6 (Roche) per well. A Renilla luciferase reporter (10 ng of pRL-TK, Promega) was included to control for transfection efficiency. After 24 h, medium was replaced with fresh media with or without 30 ng/ml TNFa. After an additional 48 h, cells were lysed and firefly luciferase and renilla luciferase activities were determined using the Dual-Luciferase Reporter Assay system (Promega). For p65/ RelA co-transfection experiments, 2.0 Â 10 5 MCF7 cells were seeded in six-well plates and transfected the following day with 500 ng of pTMS1-1254-Luc plus 0-2 mg of a human p65/RelA expression construct (pcDNA-p65, a gift from Dr Jeremy Boss, Emory University) using Lipofectamine. Renilla luciferase plasmid (pRL-TK, 50 ng) was included as a control. The total amount of DNA was kept constant at 2.5 mg using pcDNA3.1 (Invitrogen). After 48 h, luciferase activities were determined using the Dual-Luciferase Reporter Assay system (Promega).
